Open Access Research article

Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

Lambros Vamvakas, Alexios Matikas, Athanasios Karampeazis, Dora Hatzidaki, Stelios Kakolyris, Charalampos Christophylakis, Ioannis Boukovinas, Aris Polyzos, Vassilis Georgoulias and John Souglakos*

BMC Cancer 2014, 14:277  doi:10.1186/1471-2407-14-277

PubMed Commons is an experimental system of commenting on PubMed abstracts, introduced in October 2013. Comments are displayed on the abstract page, but during the initial closed pilot, only registered users can read or post comments. Any researcher who is listed as an author of an article indexed by PubMed is entitled to participate in the pilot. If you would like to participate and need an invitation, please email info@biomedcentral.com, giving the PubMed ID of an article on which you are an author. For more information, see the PubMed Commons FAQ.

Post a comment